IDST for BTKi AEs
Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies

Released: January 07, 2025

Expiration: January 06, 2026

Instructions

This Interactive Decision Support Tool provides BTK inhibitor–associated AE management recommendations from a consensus of 5 experts based on the specific patient characteristics you enter in the tool. It is recommended that you have as much information as possible available before you begin.

You will first be asked whether the patient has received or is planning to begin BTK inhibitor therapy, and you will then be prompted to provide specific information about the patient, such as whether patient is experiencing an AE or planning an invasive medical procedure, the type of AE the patient is experiencing, and the grade of the AE.

Click on your selections. Your choices can be changed at any time simply by reviewing your saved answers, clicking on the [Change] link by your current answer, and selecting a new choice.

Additional information on each variable/characteristic and why it is important for making management selections is available by clicking on the [i] icon after each selection.

When all patient characteristics are entered, you will be asked to select the management option you are currently planning. Once that information is entered, you can click the Submit Case button to view the expert recommendations.

After reviewing your case-specific recommendations, you will be asked brief questions about how the recommendations influenced your decision-making. You will then be able to enter a new case scenario by clicking the Start New Case button.

Additional sections appear in the table of contents menu that provide more information about this tool: About This Tool, Instructions, and References.

You will also be able to print/download the recommendations along with a summary of the patient characteristics and selected therapy you entered by clicking the Case Summary button.

Note: The current tool was developed in November 2024 and reflects the expert recommendations at that time.

Access to and use of this Interactive Decision Support Tool titled, “Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies” is provided subject to the following terms and conditions. PLEASE READ THESE TERMS CAREFULLY.

This Interactive Decision Support Tool is designed to educate healthcare professionals on making optimal management choices in monitoring and managing adverse events that can occur in patients with cancer treated with BTK inhibitor therapy with expert guidance from: Toby A Eyre, MBChB, MD; Arnon Kater, MD, PhD; Vincent Ribrag, MD; Stephan Stilgenbauer, MD; and Alessandra Tedeschi, MD.

The material published by Clinical Care Options reflects the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Although the information contained in the “Interactive Tool to Guide Management of Adverse Events With BTK Inhibitor Therapy in Hematologic Malignancies” Interactive Decision Support Tool has been produced and processed from sources believed to be reliable, no warranty, expressed or implied, is made regarding the accuracy, adequacy, completeness, legality, reliability, or usefulness of any information. This disclaimer applies to both the isolated and aggregate uses of the information. Clinical Care Options provides this information on an as-is basis. This disclaimer applies to all material published by Clinical Care Options including but not limited to medical information or opinions. All warranties of any kind, expressed or implied, including but not limited to the implied warranties of merchantability, fitness for a particular purpose, freedom from contamination by computer viruses, and noninfringement of proprietary rights are disclaimed.

Any trademarks are the property of respective companies.

© 2024 Clinical Care Options, LLC. All rights reserved.

Program Content